The investor has entered a "all-in" position in HIMS at an average price of $26.72, citing a 34% short interest and upcoming earnings on May 11 as potential catalysts for a short squeeze. The bullish thesis highlights HIMS's distribution network for peptides and branded Wegovy, though risks include margin compression and a legal suit from Novo Nordisk. To fund this trade, the investor sold their position in IREN at $61.85 but remains bullish on the stock for a potential return next week.